Fully human IgG4 mAb binding IL-4Rα subunit shared by IL-4 + IL-13 receptors → blocks both Th2 cytokines. Paradigm-shifting treatment for atopic dermatitis — moderate-severe AD failed every prior systemic, dupilumab clears ~40% and improves 70–80%. Expanded to asthma, CRSwNP, EoE, prurigo nodularis.
Half-Life & Elimination Curve (SC: 21d)
Elimination (SC)
0×t½0h100%(78.4 mg/L)
1×t½21d50%(39.2 mg/L)
2×t½42d25%(19.6 mg/L)
3×t½63d12.5%(9.8 mg/L)
4×t½84d6.3%(4.9 mg/L)
5×t½105d3.1%(2.45 mg/L)
Elimination t½21d (SC)
Rate Constant (ke)0.00138 h⁻¹
Est. Peak (Cmax)78.4 mg/L
Clearance (CL)0.00674 L/h
97% Washout (5×t½)105d
Dosing Guidelines
Subcutaneous (SC): Typical 600 mg
Pharmacokinetic Parameters
Subcutaneous (SC): Bioavailability (F): 64% · Volume of Distribution (Vd): 4.9 L [PMID 27690741]